| Home | E-Submission | Sitemap | Contact Us |  
top_img
The Korean Journal of Pathology 2004;38(6): 372-377.
Expression of Melanoma Antigen Gene (MAGE) and Synovial Sarcoma on X chromosome (SSX) in Ovarian Tumors.
Young Ok Kim, Jean Kyung Park, Kwang Hui Kim, Jong Wook Park, Chang Ho Cheon, Won Kim, Hee Kyung Chang
1Department of Pathology, Kosin Universitiy School of Medicine, Busan, Korea. changhkg@ns.kosinmed.or.kr
2Department of Immunology, Medical College of Keimyung University, Daegu, Korea.
3Department of Laboratory Medicine, Medical College of Daegu-Catholic University, Daegu, Korea.
4Department of Medical Administration, Kyungnam College of Information and Technology, Busan, Korea.
ABSTRACT
BACKGROUND: Several cancer-testis antigen genes or gene families have been isolated to date, including Melanoma Antigen Gene (MAGE) and Synovial Sarcoma on X chromosome (SSX). This study attempted to investigate the possibility of immunotherapy for ovarian cancer and to explore the prevalence of the expression of MAGE and SSX. METHODS: The fresh tissue samples were obtained from 5 cases of normal ovaries, 6 cases of non-neoplastic disease, 21 cases of benign ovarian tumors, and 12 cases of malignant ovarian tumors. The expression of MAGE A1-6 and SSX 1-9 was detected by nested reverse transcriptionpolymerase chain reaction using each common primers sets for MAGE A1-6 and SSX 1-9. RESULTS: The expression rate of MAGE 1-6 mRNA was 23.0% (5/21) for the benign ovarian tumors and 91.7% (11/12) for the malignant ovarian tumor, whereas the normal ovaries (0/5) and non-neoplastic ovarian tissues (0/6) did not express MAGE (p<0.05). The expression rate of SSX was 40.0% (2/5) for the normal ovaries, 23.0% (5/21) for the benign ovarian tumors, and 33.3% (4/12) for the malignant ovarian tumors, while the non-neoplastic ovarian tissues showed no expression of SSX (p>0.05). A relationship between the two genes was not observed (kappa coefficient=0.32). CONCLUSION: These results suggest that the gene products of MAGE and SSX can be useful for the immunotherapy of ovarian cancer patients and that MAGE can be a more promising target than SSX from the viewpoint of applicability and cancer-specificity.
Key Words: Ovarian cancer; MAGE; SSX; Common primers
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
Supplement  Supplement
  E-Mail
Share:      
METRICS
729
View
1
Download
Related article
Expression of Proliferating Cell Nuclear Antigen and p53 Protein in Ovarian Epithelial Tumors.  1998 March;32(3)